Skip to content
OpenCapital
Get started

Integra LifeSciences IART EPS (Diluted)

EPS (Diluted) at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$1.11-204%
Stryker logo
StrykerSYK
$1.93+14.2%
Axogen logo
AxogenAXGN
-$0.38-375%
AbbVie logo
AbbVieABBV
$0.39-45.8%
Medtronic logo
MedtronicMDT
$0.97+18.3%
STERIS logo
STERISSTE
$2.24+52.4%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's EPS (diluted)?
Integra LifeSciences (IART) reported EPS (diluted) of -$0.06 in Q1 2026.
How has Integra LifeSciences's EPS (diluted) changed year-over-year?
Integra LifeSciences's EPS (diluted) increased by 81.8% year-over-year, from -$0.33 to -$0.06.
What is the long-term trend for Integra LifeSciences's EPS (diluted)?
Over 3 years (2021 to 2025), Integra LifeSciences's EPS (diluted) has grown at a 50.4% compound annual growth rate (CAGR), from $1.98 to -$6.73.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.